The placental gene PEG10 promotes progression of neuroendocrine prostate cancer

Cell Reports

Volumn 12, Issue 6, 2015, Pages 922-936

  Akamatsu, Shusuke ^a,b   Wyatt, Alexander W ^a,b   Lin, Dong ^a,b,c   Lysakowski, Summer ^a,b   Zhang, Fan ^a,b   Kim, Soojin ^a,b   Tse, Charan ^a,b   Wang, Kendric ^a,b   Mo, Fan ^a,b   Haegert, Anne ^a,b   Brahmbhatt, Sonal ^a,b   Bell, Robert ^a,b   Adomat, Hans ^a,b   Kawai, Yoshihisa ^a,b   Xue, Hui ^c   Dong, Xin ^c   Fazli, Ladan ^a,b   Tsai, Harrison ^d   Lotan, Tamara L ^d   Kossai, Myriam ^e,f   Mosquera, Juan Miguel ^e,f   Rubin, Mark A ^e,f   Beltran, Himisha ^e,f   Zoubeidi, Amina ^a,b   Wang, Yuzhuo ^a,b,c   Gleave, Martin E ^a,b   Collins, Colin C ^a,b   more..

^a VANCOUVER PROSTATE CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ISOPROTEIN; PROTEIN P53; PROTEIN PEG10; PROTEIN RB1; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; UNCLASSIFIED DRUG; PEG10 PROTEIN, HUMAN; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; MOUSE; NEUROENDOCRINE PROSTATE CANCER; NONHUMAN; PEG10 GENE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; CELL DIVISION; CELL MOTION; DRUG SCREENING; GENETICS; MALE; METABOLISM; NEUROSECRETORY CELL; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; MALE; MICE; MICE, SCID; NEUROENDOCRINE CELLS; PROSTATIC NEOPLASMS; PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947045416     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.07.012     Document Type: Article

References (51)

1. Akhurst, R.J., and Hata, A. (2012). Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790-811.
2. Aparicio, A.M., Harzstark, A.L., Corn, P.G., Wen, S., Araujo, J.C., Tu, S.M., Pagliaro, L.C., Kim, J., Millikan, R.E., Ryan, C., et al. (2013). Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 19, 3621-3630.
3. Attard, G., Cooper, C.S., and de Bono, J.S. (2009). Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16, 458-462.
4. Beltran, H., Rickman, D.S., Park, K., Chae, S.S., Sboner, A., MacDonald, T.Y., Wang, Y., Sheikh, K.L., Terry, S., Tagawa, S.T., et al. (2011). Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487-495.
5. Beltran, H., Tagawa, S.T., Park, K., MacDonald, T., Milowsky, M.I., Mosquera, J.M., Rubin, M.A., and Nanus, D.M. (2012). Challenges in recognizing treatment- related neuroendocrine prostate cancer. J. Clin. Oncol. 30, e386-e389.
6. Beltran, H., Tomlins, S., Aparicio, A., Arora, V., Rickman, D., Ayala, G., Huang, J., True, L., Gleave, M.E., Soule, H., et al. (2014). Aggressive variants of castration- resistant prostate cancer. Clin. Cancer Res. 20, 2846-2850.
7. Brandl, M., Seidler, B., Haller, F., Adamski, J., Schmid, R.M., Saur, D., and Schneider, G. (2010). IKK(α) controls canonical TGF(ß)-SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in panc1 cells. J. Cell Sci. 123, 4231-4239.
8. Chandran, U.R., Ma, C., Dhir, R., Bisceglia, M., Lyons-Weiler, M., Liang, W., Michalopoulos, G., Becich, M., and Monzon, F.A. (2007). Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7, 64.
9. Chen, H., Sun, Y., Wu, C., Magyar, C.E., Li, X., Cheng, L., Yao, J.L., Shen, S., Osunkoya, A.O., Liang, C., and Huang, J. (2012). Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr. Relat. Cancer 19, 321-331.
10. Cindolo, L., Cantile, M., Vacherot, F., Terry, S., and de la Taille, A. (2007). Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol. Int. 79, 287-296.
11. Clark, M.B., Jänicke, M., Gottesbühren, U., Kleffmann, T., Legge, M., Poole, E.S., and Tate, W.P. (2007). Mammalian gene PEG10 expresses two reading frames by high efficiency -1 frameshifting in embryonic-associated tissues. J. Biol. Chem. 282, 37359-37369.
12. de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K.N., Jones, R.J., Goodman, O.B., Jr., Saad, F., et al.; COU-AA-301 Investigators (2011). Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005.
13. Dimri, G.P., Nakanishi, M., Desprez, P.Y., Smith, J.R., and Campisi, J. (1996). Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol. Cell. Biol. 16, 2987-2997.
14. Epstein, J.I., Amin, M.B., Beltran, H., Lotan, T.L., Mosquera, J.M., Reuter, V.E., Robinson, B.D., Troncoso, P., and Rubin, M.A. (2014). Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 38, 756-767.
15. Ertel, A., Dean, J.L., Rui, H., Liu, C., Witkiewicz, A.K., Knudsen, K.E., and Knudsen, E.S. (2010). RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 9, 4153-4163.
16. Grasso, C.S., Wu, Y.M., Robinson, D.R., Cao, X., Dhanasekaran, S.M., Khan, A.P., Quist, M.J., Jing, X., Lonigro, R.J., Brenner, J.C., et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243.
17. Guo, C.C., Dancer, J.Y., Wang, Y., Aparicio, A., Navone, N.M., Troncoso, P., and Czerniak, B.A. (2011). TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum. Pathol. 42, 11-17.
18. Hamed, M., Ismael, S., Paulsen, M., and Helms, V. (2012). Cellular functions of genetically imprinted genes in human and mouse as annotated in the gene ontology. PLoS ONE 7, e50285.
19. Haram, K.M., Peltier, H.J., Lu, B., Bhasin, M., Otu, H.H., Choy, B., Regan, M., Libermann, T.A., Latham, G.J., Sanda, M.G., and Arredouani, M.S. (2008). Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Prostate 68, 1517-1530.
20. Kastner, S., Voss, T., Keuerleber, S., Glöckel, C., Freissmuth, M., and Sommergruber, W. (2012). Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-M cellcycle progression. Mol. Cancer Res. 10, 1343-1358.
21. Kumar, A., White, T.A., MacKenzie, A.P., Clegg, N., Lee, C., Dumpit, R.F., Coleman, I., Ng, S.B., Salipante, S.J., Rieder, M.J., et al. (2011). Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA 108, 17087-17092.
22. Lamouille, S., Xu, J., and Derynck, R. (2014). Molecular mechanisms of epithelial- mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178-196.
23. Li, X., Placencio, V., Iturregui, J.M., Uwamariya, C., Sharif-Afshar, A.R., Koyama, T., Hayward, S.W., and Bhowmick, N.A. (2008). Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 27, 7118-7130.
24. Lin, D., Wyatt, A.W., Xue, H., Wang, Y., Dong, X., Haegert, A., Wu, R., Brahmbhatt, S., Mo, F., Jong, L., et al. (2014). High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74, 1272-1283.
25. Lotan, T.L., Gupta, N.S., Wang, W., Toubaji, A., Haffner, M.C., Chaux, A., Hicks, J.L., Meeker, A.K., Bieberich, C.J., De Marzo, A.M., et al. (2011). ERG gene rearrangements are common in prostatic small cell carcinomas. Mod. Pathol. 24, 820-828.
26. Lux, H., Flammann, H., Hafner, M., and Lux, A. (2010). Genetic and molecular analyses of PEG10 reveal new aspects of genomic organization, transcription and translation. PLoS ONE 5, e8686.
27. Moore, T., and Haig, D. (1991). Genomic imprinting in mammalian development: a parental tug-of-war. Trends Genet. 7, 45-49.
28. Morison, I.M., Ramsay, J.P., and Spencer, H.G. (2005). A census of mammalian imprinting. Trends Genet. 21, 457-465.
29. Nelson, E.C., Cambio, A.J., Yang, J.C., Ok, J.H., Lara, P.N., Jr., and Evans, C.P. (2007). Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis. 10, 6-14.
30. Ono, R., Kobayashi, S., Wagatsuma, H., Aisaka, K., Kohda, T., Kaneko-Ishino, T., and Ishino, F. (2001). A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics 73, 232-237.
31. Ono, R., Nakamura, K., Inoue, K., Naruse, M., Usami, T., Wakisaka-Saito, N., Hino, T., Suzuki-Migishima, R., Ogonuki, N., Miki, H., et al. (2006). Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality. Nat. Genet. 38, 101-106.
32. Peinado, H., Olmeda, D., and Cano, A. (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415-428.
33. Pezaro, C.J., Omlin, A., Lorente, D., Nava Rodrigues, D., Ferraldeschi, R., Bianchini, D., Mukherji, D., Riisnaes, R., Altavilla, A., Crespo, M., et al. (2014). Visceral disease in castration-resistant prostate cancer. Eur. Urol. 65, 270-273.
34. Rousseaux, S., Debernardi, A., Jacquiau, B., Vitte, A.L., Vesin, A., Nagy-Mignotte, H., Moro-Sibilot, D., Brichon, P.Y., Lantuejoul, S., Hainaut, P., et al. (2013). Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci. Transl. Med. 5, 186ra66.
35. Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., de Wit, R., Mulders, P., Chi, K.N., Shore, N.D., et al.; AFFIRM Investigators (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197.
36. Shiota, M., Zardan, A., Takeuchi, A., Kumano, M., Beraldi, E., Naito, S., Zoubeidi, A., and Gleave, M.E. (2012). Clusterin mediates TGF-β-induced epithelial- mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res. 72, 5261-5272.
37. Smith, A.P., Verrecchia, A., Fagà, G., Doni, M., Perna, D., Martinato, F., Guccione, E., and Amati, B. (2009). A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 28, 422-430.
38. Spurgers, K.B., Gold, D.L., Coombes, K.R., Bohnenstiehl, N.L., Mullins, B., Meyn, R.E., Logothetis, C.J., and McDonnell, T.J. (2006). Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J. Biol. Chem. 281, 25134-25142.
39. Sun, Y., Campisi, J., Higano, C., Beer, T.M., Porter, P., Coleman, I., True, L., and Nelson, P.S. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18, 1359-1368.
40. Takeuchi, T., Tomida, S., Yatabe, Y., Kosaka, T., Osada, H., Yanagisawa, K., Mitsudomi, T., and Takahashi, T. (2006). Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J. Clin. Oncol. 24, 1679-1688.
41. Tan, H.L., Sood, A., Rahimi, H.A., Wang, W., Gupta, N., Hicks, J., Mosier, S., Gocke, C.D., Epstein, J.I., Netto, G.J., et al. (2014). Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20, 890-903.
42. Terry, S., and Beltran, H. (2014). The many faces of neuroendocrine differentiation in prostate cancer progression. Front. Oncol. 4, 60.
43. Tomlins, S.A., Mehra, R., Rhodes, D.R., Cao, X., Wang, L., Dhanasekaran, S.M., Kalyana-Sundaram, S., Wei, J.T., Rubin, M.A., Pienta, K.J., et al. (2007). Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41-51.
44. Varambally, S., Yu, J., Laxman, B., Rhodes, D.R., Mehra, R., Tomlins, S.A., Shah, R.B., Chandran, U., Monzon, F.A., Becich, M.J., et al. (2005). Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406.
45. Wang, C., Xiao, Y., Hu, Z., Chen, Y., Liu, N., and Hu, G. (2008). PEG10 directly regulated by E2Fs might have a role in the development of hepatocellular carcinoma. FEBS Lett. 582, 2793-2798.
46. Wilding, G., Zugmeier, G., Knabbe, C., Flanders, K., and Gelmann, E. (1989). Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol. Cell. Endocrinol. 62, 79-87.
47. Williamson, S.R., Zhang, S., Yao, J.L., Huang, J., Lopez-Beltran, A., Shen, S., Osunkoya, A.O., MacLennan, G.T., Montironi, R., and Cheng, L. (2011). ERGTMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod. Pathol. 24, 1120-1127.
48. Wu, Y., Fu, Y., Zheng, L., Lin, G., Ma, J., Lou, J., Zhu, H., He, Q., and Yang, B. (2014). Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis. Cancer Lett. 342, 82-91.
49. Wyatt, A.W., Mo, F., Wang, K., McConeghy, B., Brahmbhatt, S., Jong, L., Mitchell, D.M., Johnston, R.L., Haegert, A., Li, E., et al. (2014). Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol. 15, 426.
50. Yu, J., Yu, J., Mani, R.S., Cao, Q., Brenner, C.J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454.
51. Zavadil, J., and Böttinger, E.P. (2005). TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24, 5764-5774.